JP2009280573A - Body odor inhibitor for internal use - Google Patents
Body odor inhibitor for internal use Download PDFInfo
- Publication number
- JP2009280573A JP2009280573A JP2009101565A JP2009101565A JP2009280573A JP 2009280573 A JP2009280573 A JP 2009280573A JP 2009101565 A JP2009101565 A JP 2009101565A JP 2009101565 A JP2009101565 A JP 2009101565A JP 2009280573 A JP2009280573 A JP 2009280573A
- Authority
- JP
- Japan
- Prior art keywords
- body odor
- internal use
- citronellal
- limonene
- citronellol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035985 Body Odor Diseases 0.000 title claims abstract description 37
- 206010040904 Skin odour abnormal Diseases 0.000 title claims abstract description 37
- 239000003112 inhibitor Substances 0.000 title claims abstract description 9
- NEHNMFOYXAPHSD-UHFFFAOYSA-N citronellal Chemical compound O=CCC(C)CCC=C(C)C NEHNMFOYXAPHSD-UHFFFAOYSA-N 0.000 claims abstract description 48
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 44
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims abstract description 38
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims abstract description 38
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229930003633 citronellal Natural products 0.000 claims abstract description 24
- 235000000983 citronellal Nutrition 0.000 claims abstract description 24
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims abstract description 24
- 235000001510 limonene Nutrition 0.000 claims abstract description 24
- 229940087305 limonene Drugs 0.000 claims abstract description 24
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims abstract description 21
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims abstract description 19
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940043350 citral Drugs 0.000 claims abstract description 19
- 235000000484 citronellol Nutrition 0.000 claims abstract description 19
- 239000005792 Geraniol Substances 0.000 claims abstract description 18
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims abstract description 18
- 229940113087 geraniol Drugs 0.000 claims abstract description 18
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims abstract description 17
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims abstract description 17
- 229930007744 linalool Natural products 0.000 claims abstract description 17
- -1 monoterpene compound Chemical class 0.000 claims abstract description 16
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims abstract description 13
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000012141 vanillin Nutrition 0.000 claims abstract description 12
- 229930003658 monoterpene Natural products 0.000 claims abstract description 9
- 235000002577 monoterpenes Nutrition 0.000 claims abstract description 9
- 239000013589 supplement Substances 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 12
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- CZVXBFUKBZRMKR-UHFFFAOYSA-N lavandulol Chemical compound CC(C)=CCC(CO)C(C)=C CZVXBFUKBZRMKR-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- YSTPAHQEHQSRJD-SECBINFHSA-N (-)-piperitone Chemical compound CC(C)[C@H]1CCC(C)=CC1=O YSTPAHQEHQSRJD-SECBINFHSA-N 0.000 description 1
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- HPZWSJQQCJZBBG-LQPGMRSMSA-N (3E,5E)-2,6-Dimethyl-1,3,5,7-octatetraene Chemical compound CC(=C)\C=C\C=C(/C)C=C HPZWSJQQCJZBBG-LQPGMRSMSA-N 0.000 description 1
- HPZWSJQQCJZBBG-UHFFFAOYSA-N (3E,5E)-2,6-dimethyl-1,3,5,7-octatetraene Natural products CC(=C)C=CC=C(C)C=C HPZWSJQQCJZBBG-UHFFFAOYSA-N 0.000 description 1
- NHMKYUHMPXBMFI-SNVBAGLBSA-N (4s)-2-methyl-6-methylideneocta-2,7-dien-4-ol Chemical compound CC(C)=C[C@@H](O)CC(=C)C=C NHMKYUHMPXBMFI-SNVBAGLBSA-N 0.000 description 1
- CZVXBFUKBZRMKR-JTQLQIEISA-N (R)-lavandulol Natural products CC(C)=CC[C@@H](CO)C(C)=C CZVXBFUKBZRMKR-JTQLQIEISA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- VBIRCRCPHNUJAS-AFHBHXEDSA-N 4-[(1S,3aR,4S,6aR)-4-(1,3-benzodioxol-5-yl)tetrahydrofuro[3,4-c]furan-1-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C4OCOC4=CC=3)CO2)=C1 VBIRCRCPHNUJAS-AFHBHXEDSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000134874 Geraniales Species 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- NHMKYUHMPXBMFI-UHFFFAOYSA-N Ipsdienol-d Natural products CC(C)=CC(O)CC(=C)C=C NHMKYUHMPXBMFI-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001260 acyclic compounds Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- WTEVQBCEXWBHNA-YFHOEESVSA-N citral B Natural products CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000001319 headspace solid-phase micro-extraction Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- 238000004853 microextraction Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- VPSRGTGHZKLTBU-UHFFFAOYSA-N piperitol Natural products COc1ccc(cc1OCC=C(C)C)C2OCC3C2COC3c4ccc5OCOc5c4 VPSRGTGHZKLTBU-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- 229940116411 terpineol Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- HPOHAUWWDDPHRS-UHFFFAOYSA-N trans-piperitol Natural products CC(C)C1CCC(C)=CC1O HPOHAUWWDDPHRS-UHFFFAOYSA-N 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、内服で即効性かつ持続性を有する体臭を抑制するための剤及びその利用に関する。 The present invention relates to an agent for suppressing body odor having immediate effect and durability in internal use and use thereof.
「体臭」は食生活、健康状態、年齢によって変化することが知られているため、生活習慣や健康のバロメータとして有用であるとも考えられる。しかし、多くの人にとって他人の体臭は、その匂いの強弱にも依存するが、一般に不快な臭いとして受け取られることが多い。その体臭が強いがゆえに現代社会における円滑な共同生活が妨げられることもある。 Since “body odor” is known to change depending on diet, health condition, and age, it may be useful as a barometer of lifestyle and health. However, for many people, the body odor of others is generally perceived as an unpleasant odor, depending on the intensity of the odor. Because of its strong body odor, it may interfere with smooth communal living in modern society.
フィチン酸（特許文献１参照）、藍藻類の藻体（特許文献２参照）、特定の生薬（特許文献３参照）、植物由来のポリフェノール（特許文献４参照）等を内服することにより体臭が抑制されることが知られている。 Body odor is suppressed by taking phytic acid (see Patent Document 1), cyanobacterial algae (see Patent Document 2), specific herbal medicine (see Patent Document 3), plant-derived polyphenol (see Patent Document 4), etc. It is known that
外用投与としては、香気成分を含有する体臭発生抑制化粧料（特許文献５参照）、香料化合物を単糖類で配糖体にした人体表面用徐放性芳香組成物（特許文献６参照）、精油または精油成分からなるデオドラント剤（特許文献７参照）等を外用投与することにより体臭が抑制されることが知られている。 For topical administration, body odor generation-suppressing cosmetics containing fragrance components (see Patent Document 5), sustained release fragrance compositions for human surfaces in which fragrance compounds are glycosided with monosaccharides (see Patent Document 6), essential oils Alternatively, it is known that body odor is suppressed by externally administering a deodorant agent composed of an essential oil component (see Patent Document 7) or the like.
しかし、リモネン、シトロネラール、シトロネロール又はシトラールのような非芳香族モノテルペン化合物を内服することによって体臭抑制作用が発現したという事実はこれまでに知られていない。 However, the fact that a body odor suppressing action has been developed by taking a non-aromatic monoterpene compound such as limonene, citronellal, citronellol or citral has not been known so far.
本発明者らは、現代社会において、円滑かつ快適な社会生活の観点から、内服により優れた体臭の抑制効果を有する化合物を提供することが、有用であると考えて研究を開始した。すなわち、内服により優れた体臭の抑制効果を有する化合物の有用な用途としては、医薬品、サプリメント、飲食品等の有効成分としての利用が考えられる。 In the modern society, the present inventors started research on the belief that it would be useful to provide a compound having an excellent body odor suppression effect by internal use from the viewpoint of a smooth and comfortable social life. That is, as a useful use of a compound having an excellent body odor suppressing effect by internal use, use as an active ingredient of pharmaceuticals, supplements, foods and drinks, and the like can be considered.
本発明者らは、長年に渡り鋭意研究を続けた結果、非芳香族モノテルペン化合物が、内服により優れた体臭の抑制効果を有することを発見した。 As a result of intensive studies over many years, the present inventors have found that non-aromatic monoterpene compounds have an excellent body odor suppressing effect by internal use.
非芳香族モノテルペン化合物の中でも、
非環式化合物としては、ミルセン、オシメン、コスメン、リナロール、ゲラニオール、ネロール、シトロネロール、ミルセノール、ラバンジュロール、イプスジエノール、シトラール（ネラール、ゲラニアール）、シトロネラール、ゲラニル酸等が知られている。
Among non-aromatic monoterpene compounds,
As acyclic compounds, myrcene, osimene, cosmene, linalool, geraniol, nerol, citronellol, myrsenol, lavandulol, ipsdienol, citral (neral, geranial), citronellal, geranilic acid, etc. are known.
環式化合物としては、メンタン、リモネン、フェランドレン、テルピノレン、テルピネン、シメン、メントール、プレゴール、ピペリトール、テルピネオール、カルベオール、チモール、アネトール、ジヒドロカルベオール、メントン、プレゴン、フェランドラール、カルボン、カルベノン、ピペリトン等が知られている。 Examples of cyclic compounds include menthane, limonene, ferrandolene, terpinolene, terpinene, cymen, menthol, pregol, piperitol, terpineol, carveol, thymol, anethole, dihydrocarbeveol, menthone, pregon, ferrandral, carvone, carbenone, piperiton, etc. It has been known.
本発明者らは、数多く知られている非芳香族モノテルペン化合物の中でも、特に、リモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール及びリナロールについて、優れた効果を有することを発見し、更に詳細に、リモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール及びリナロールについて、内服した場合の体外発散特性を比較、検討した。 The present inventors have found that among many known non-aromatic monoterpene compounds, particularly limonene, citronellal, citronellol, citral, geraniol and linalool have excellent effects, and more particularly, limonene Citronellal, citronellol, citral, geraniol, and linalool were compared and examined for their ex vivo divergence characteristics when taken orally.
その比較試験の結果、リモネン、シトロネラール、シトロネロール及びシトラールが、ゲラニオール及びリナロールと比較して、特に優れた即効性と持続性効果を併せ持つことを見出し、本発明を完成させるに至った。 As a result of the comparative test, it was found that limonene, citronellal, citronellol and citral have both excellent immediate effects and sustainability effects compared to geraniol and linalool, and the present invention was completed.
すなわち本発明は、（１）リモネン、シトロネラール、シトロネロール又はシトラールである非芳香族モノテルペン化合物からなる内服用体臭抑制剤であり、好適には、
（２）非芳香族モノテルペン化合物がリモネン及びシトロネラールである（１）に記載の内服用体臭抑制剤、
（３）さらに、ゲラニオール、リナロール又はバニリンを含有する（１）又は（２）に記載の内服用体臭抑制剤、
（４）即効性かつ持続性を有する（１）〜（３）のいずれか１項に記載の内服用体臭抑制剤及び
（５）（１）〜（４）のいずれか１項に記載の内服用体臭抑制剤を有効成分として含有する医薬組成物、サプリメント又は飲食品である。
That is, the present invention is (1) a body odor suppressor for internal use comprising a non-aromatic monoterpene compound which is limonene, citronellal, citronellol or citral,
(2) The internal odor inhibitor for internal use according to (1), wherein the non-aromatic monoterpene compound is limonene and citronellal,
(3) The body odor suppressor for internal use according to (1) or (2), further comprising geraniol, linalool or vanillin,
(4) Immediate and long-lasting body odor inhibitor according to any one of (1) to (3) and (5) (1) to (4) It is a pharmaceutical composition, supplement or food or drink containing a body odor suppressor as an active ingredient.
本発明のリモネン、シトロネラール、シトロネロール又はシトラールからなる内服用体臭抑制剤は、共同社会生活を円滑にするために有用である。また、本発明の体臭抑制剤は、即効性と持続性効果を併せ持つことから有用である。すなわち、内服により優れた体臭の抑制効果を有することから、医薬品、サプリメント、飲食品等の有効成分としての利用が考えられる。 The body odor control agent for internal use comprising limonene, citronellal, citronellol or citral of the present invention is useful for facilitating community life. The body odor suppressor of the present invention is useful because it has both an immediate effect and a long-lasting effect. That is, since it has an excellent body odor suppressing effect by internal use, it can be used as an active ingredient of pharmaceuticals, supplements, foods and drinks, and the like.
本発明に使用されるリモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール、リナロール、バニリン等は指定食品添加物リストに収載されている。 Limonene, citronellal, citronellol, citral, geraniol, linalool, vanillin and the like used in the present invention are included in the designated food additive list.
本発明において、リモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール、リナロール、バニリンの使用量は、例えば、食品添加物公定書に記載された経口摂取の安全量の範囲内であるが、本発明の効果を発揮するためには、通常、これらの化合物が、香料として使用されている量では足りず、その使用量は明確に区別できるものである。 In the present invention, the amount of limonene, citronellal, citronellol, citral, geraniol, linalool, and vanillin is within the range of the safe amount for oral intake described in the Food Additives Standard, for example. In order to exhibit, usually, the amount of these compounds used as a fragrance is not sufficient, and the amount used can be clearly distinguished.
本発明において、リモネン、シトロネラール、シトロネロールまたはシトラールと、ゲラニオール、リナロールまたはバニリンとの配合比も、各成分が安全量の範囲内にあれば特に限定されない。 In the present invention, the mixing ratio of limonene, citronellal, citronellol or citral and geraniol, linalool or vanillin is not particularly limited as long as each component is within a safe range.
リモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール、リナロール、バニリンの１回あたりの合計の服用又は摂取量は、年齢により異なるが、通常２ｍｇ〜３０００ｍｇであり、好適には、５ｍｇ〜１０００ｍｇこれを１日に、１〜３回服用又は摂取する（これに対して、通常、香料として用いる場合には、０．０１ｍｇ〜１ｍｇである）。 The total dose or intake of limonene, citronellal, citronellol, citral, geraniol, linalool, vanillin varies depending on the age, but is usually 2 mg to 3000 mg, preferably 5 mg to 1000 mg per day. 1 to 3 times or taken (in contrast, when used as a fragrance, it is usually 0.01 mg to 1 mg).
本発明の剤を組成物として用いる場合、剤形が液剤又は半固形製剤の場合、１回量中に含有されるリモネン、シトロネラール、シトロネロール、シトラール、ゲラニオール、リナロール、バニリンの合計の含有量は、通常０．５重量％〜３０重量％であり、好適には、１重量％〜１０重量％である（これに対して、通常、香料として用いる場合には、０．０１重量％〜０．２重量％である）。 When the agent of the present invention is used as a composition, when the dosage form is a liquid or semi-solid preparation, the total content of limonene, citronellal, citronellol, citral, geraniol, linalool, vanillin contained in a single dose is: Usually 0.5% to 30% by weight, preferably 1% to 10% by weight (on the other hand, usually 0.01% to 0.2% when used as a fragrance). % By weight).
本発明の剤を組成物として用いる場合、その具体的な形態（剤形）としては、固形製剤、半固形製剤または液剤であり、例えば、錠剤、咀嚼錠剤、顆粒剤、散剤（細粒を含む）、カプセル剤、液剤等を挙げることができる。 When the agent of the present invention is used as a composition, the specific form (dosage form) is a solid preparation, a semi-solid preparation or a liquid, for example, a tablet, a chewing tablet, a granule, a powder (including fine granules). ), Capsules, liquids and the like.
本発明の剤を組成物として用いる場合、その製剤を製造するにあたっては、各剤形に適した医薬品添加物、その他の食品添加物、基材等を適宜使用し、日本薬局方等に記載された通常の方法に従い、製造することができる。 When the agent of the present invention is used as a composition, pharmaceutical preparations suitable for each dosage form, other food additives, base materials, etc. are used as appropriate in the preparation of the preparation, and are described in the Japanese Pharmacopoeia. According to the usual method, it can be manufactured.
例えば、本発明の剤を組成物として用いる場合、その剤形が錠剤の場合、賦形剤としては通常の製剤に用いられるものを、結合剤としてはヒドロキシプロピルセルロース、ポリビニルアルコール等を、滑沢剤としてはステアリン酸マグネシウム、タルク等を使用することができる。 For example, when the agent of the present invention is used as a composition, when the dosage form is a tablet, the excipient used is an ordinary formulation, the binder is hydroxypropylcellulose, polyvinyl alcohol, etc. As the agent, magnesium stearate, talc or the like can be used.
また、本発明の剤を組成物として用いる場合、その剤形が散剤及びカプセル剤の場合、賦形剤としては通常の製剤に用いられるものを、結合剤としては、ヒドロキシプロピルセルロース、ポリビニルアルコール等を使用することができる。 In addition, when the agent of the present invention is used as a composition, when the dosage form is a powder or capsule, the excipient is that used in ordinary preparations, the binder is hydroxypropylcellulose, polyvinyl alcohol, etc. Can be used.
その他、各形態（剤形）において、必要に応じ、クロスポビドン、低置換度ヒドロキシプロピルセルロース、カルメロース等の崩壊剤、ポリソルベート等の界面活性剤、ケイ酸カルシウム、軽質無水ケイ酸等の吸着剤、三二酸化鉄やカラメル等の着色剤、安息香酸ナトリウム等の安定剤、ｐＨ調節剤、香料、及びその他の添加物等を配合することができる。 In addition, in each form (dosage form), if necessary, disintegrants such as crospovidone, low-substituted hydroxypropylcellulose, carmellose, surfactants such as polysorbate, adsorbents such as calcium silicate and light anhydrous silicic acid, Coloring agents such as iron sesquioxide and caramel, stabilizers such as sodium benzoate, pH regulators, fragrances, and other additives can be blended.
本発明の剤を組成物として用いる場合、その組成物の剤形が飲食品の場合でも、公知の製造技術により製造することができる。 When the agent of the present invention is used as a composition, it can be produced by a known production technique even when the dosage form of the composition is a food or drink.
以下に、実施例及び試験例を示し、本発明をさらに詳細に説明するが、本発明の範囲はこれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples, but the scope of the present invention is not limited thereto.
（実施例１）錠剤
（１）成分
（表１）
１〜３錠中 （ｍｇ） （ｍｇ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
リモネン、シトロネラール、又は、
シトロネロール、シトラール １２０ ８０
ゲラニオール、リナロール、又は、
バニリン − ４０
タルク ３０ ３０
ステアリン酸マグネシウム １０ １０
ヒドロキシプロピルセルロース ５ ５
結晶セルロース ２５０ ２５０
トウモロコシ澱粉 １５０ １５０
乳糖 適量 適量
−−−−−−−−−−−−−−−−−−−−−−−−−−
（２）製法
上記成分及び分量をとり、日局製剤総則「錠剤」の項に準じて錠剤を製造する。
Example 1 Tablet (1) Ingredient (Table 1)
1 to 3 tablets (mg) (mg)
-------------------------
Limonene, citronellal, or
Citronellol, citral 120 80
Geraniol, linalool, or
Vanillin -40
Talc 30 30
Magnesium stearate 10 10
Hydroxypropyl cellulose 5 5
Crystalline cellulose 250 250
Corn starch 150 150
Lactose appropriate amount appropriate amount ---------------------
(2) Manufacturing method Take the above ingredients and the amount, and manufacture tablets according to the section of “General Tablets” “Tablet”.
（実施例２）顆粒剤
（１）成分
（表２）
１包中 （ｍｇ） （ｍｇ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
リモネン、シトロネラール、又は、
シトロネロール、シトラール １２０ ８０
ゲラニオール、リナロール、又は、
バニリン − ４０
トウモロコシ澱粉 ３５０ ３５０
ヒドロキシプロピルセルロース ５０ ５０
乳糖 適量 適量
−−−−−−−−−−−−−−−−−−−−−−−−−−
（２）製法
上記成分及び分量をとり、日局製剤総則「顆粒剤」の項に準じて細粒剤を製造する。
(Example 2) Granule (1) Ingredient (Table 2)
In 1 package (mg) (mg)
-------------------------
Limonene, citronellal, or
Citronellol, citral 120 80
Geraniol, linalool, or
Vanillin -40
Corn starch 350 350
Hydroxypropylcellulose 50 50
Lactose appropriate amount appropriate amount ---------------------
(2) Production method Take the above ingredients and quantities, and produce a fine granule according to the section of the Japanese Pharmacopoeia General Rules “Granule”.
（実施例３）カプセル剤
（１）成分
（表３）
１〜３カプセル中 （ｍｇ） （ｍｇ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
リモネン、シトロネラール、又は、
シトロネロール、シトラール １２０ ８０
ゲラニオール、リナロール、又は、
バニリン − ４０
トウモロコシ澱粉 ３５０ ３５０
ヒドロキシプロピルセルロース ５０ ５０
乳糖 適量 適量
−−−−−−−−−−−−−−−−−−−−−−−−−−
（２）製法
上記成分及び分量をとり、日局製剤総則「顆粒剤」の項に準じて細粒剤を製造した後、カプセルに充てんして硬カプセル剤を製造する。
（実施例４）液剤
（１）成分
（表４）
５０ｍＬ中 （ｍｇ） （ｍｇ）
−−−−−−−−−−−−−−−−−−−−−−−−−−
リモネン、シトロネラール、又は、
シトロネロール、シトラール １２０ ８０
ゲラニオール、リナロール、又は、
バニリン − ４０
安息香酸ナトリウム ７０ ７０
ポリビニルアルコール ６０ ６０
白糖 ９００ ９００
精製水 残部 残部
−−−−−−−−−−−−−−−−−−−−−−−−−−
（２）製法
上記成分及び分量をとり、日局製剤総則「液剤」の項に準じて液剤を製造する。
（試験例）体臭抑制効果試験
（１）被験物質
リナロール、シトロネラール、リモネン、ゲラニオールはシグマーアルドリッチ製のものを購入して使用した。被験物質は、これらを各７．５μｇずつ等量含むアロマミックスを作製して投与した。投与液量はいずれの場合も０．２ｍＬ／Ｋｇとなるようにした。
（２）動物
ＢＡＬＢ／ｃ雄性マウスの６週齢を日本チャールズリバー（株）から購入し、温度２０〜２６℃、湿度３０〜７０％、照明時間７時〜１９時に制御されたラット飼育室内でラット用ブラケットテーパーケージに５匹ずつ入れ、飼料（マウス・ラット飼育用Ｆ−２、船橋農場製）および水フィルターを通した水道水を自由に摂取させて約１週間予備飼育した。試験開始日に肉眼で動物の健康状態を観察し良好なことを確認して体重を測定し無作為に１群５匹に群分けして用いた。
（３）方法
本発明者らによって、ヒト体表面の臭い（体臭）はマウス尿の分析により評価できることが明らかとなり（Osada K, et al, Proc.R. Soc. Lond. B270,2003 p.929-933）、さらに、ヒトの体臭を改善する物質をマウスに経口投与することによりマウス尿中の老臭物質は低下することも判った。
Example 3 Capsule (1) Ingredient (Table 3)
1-3 capsules (mg) (mg)
-------------------------
Limonene, citronellal, or
Citronellol, citral 120 80
Geraniol, linalool, or
Vanillin -40
Corn starch 350 350
Hydroxypropylcellulose 50 50
Lactose appropriate amount appropriate amount --------------------------
(2) Manufacturing method After taking the above components and quantities and preparing a fine granule according to the section of the Japanese Pharmacopoeia General Rules “Granules”, it is filled into capsules to produce hard capsules.
(Example 4) Liquid agent (1) Component (Table 4)
In 50 mL (mg) (mg)
-------------------------
Limonene, citronellal, or
Citronellol, citral 120 80
Geraniol, linalool, or
Vanillin -40
Sodium benzoate 70 70
Polyvinyl alcohol 60 60
Sucrose 900 900
Purified water remainder remainder -------------------------
(2) Manufacturing method The above ingredients and quantities are taken and a liquid preparation is produced according to the section “General preparation preparations” “Liquid preparation”.
(Test example) Body odor suppression effect test (1) Test substance Linalool, citronellal, limonene, and geraniol were purchased and used from Sigma Aldrich. The test substance was prepared and prepared as an aroma mix containing 7.5 μg of each of these. The dose volume was 0.2 mL / Kg in all cases.
(2) Animals A 6-week-old BALB / c male mouse was purchased from Charles River Japan Co., Ltd., and was controlled in a rat breeding room controlled at a temperature of 20 to 26 ° C., a humidity of 30 to 70%, and an illumination time of 7 to 19 o'clock. Five rats were placed in a rat bracket taper cage, and the animals were preliminarily raised for about one week by freely ingesting feed (F-2 for breeding mice and rats, manufactured by Funabashi Farm) and tap water through a water filter. On the day of the test, the animals were visually observed for their health and confirmed to be good, and their body weight was measured. The animals were randomly divided into 5 groups per group.
(3) Method By the present inventors, it became clear that the odor (body odor) of the human body surface can be evaluated by analyzing mouse urine (Osada K, et al, Proc. R. Soc. Lond. B270, 2003 p.929). -933) In addition, oral administration of substances that improve human body odor to mice reduced the amount of odorous substances in mouse urine.
これらの一連の研究より、マウス尿によるヒトの体臭抑制の評価が可能であり、また、マウス尿の分析はヘッドスペース固相マイクロ抽出法により行った。なお、本法が体臭成分分析に応用できることも知られている（長田，味と匂い学会誌，13(1), 2006 p.59-66）。 From these series of studies, it was possible to evaluate human body odor suppression by mouse urine, and analysis of mouse urine was performed by headspace solid-phase microextraction method. It is also known that this method can be applied to body odor component analysis (Nagata, Journal of Taste and Odor Society, 13 (1), 2006 p.59-66).
試験開始日の午後４時から５時に被験物質を経口投与した。２日目以降は午後５時前後の１日１回経口投与した。 The test substance was orally administered from 4 to 5 pm on the start day of the test. From the second day onward, it was orally administered once a day around 5 pm.
体臭物質として尿を採取した。ヘッドスペース固層マイクロ抽出法により検体を採取し、水素イオン炎検出器−ガスクロマトグラフィーによる化学分析法にて分析した。
尿中の各成分は投与前値と投与後のピーク値を差し引くことによりピーク強度を求めた。
（４）試験結果
得られた結果を図１に示す。なお、値は１群５匹の平均値である。
Urine was collected as a body odor substance. A sample was collected by a headspace solid-layer microextraction method and analyzed by a chemical analysis method using a hydrogen ion flame detector-gas chromatography.
The peak intensity of each component in urine was determined by subtracting the pre-dose value and the post-dose peak value.
(4) Test results The results obtained are shown in FIG. In addition, a value is an average value of 5 animals per group.
図１より、リモネン、シトロネラールには、ゲラニオールに比べて格段に優れた効果が認められる。 From FIG. 1, limonene and citronellal are recognized to have a significantly superior effect compared to geraniol.
本発明のリモネン、シトロネラール、シトロネロール又はシトラールからなる内服用体臭抑制剤は、共同社会生活を円滑にするために有用である。また、本発明の体臭抑制剤は、即効性と持続性効果を併せ持つことから有用である。すなわち、内服により優れた体臭の抑制効果を有することから、医薬品、サプリメント、飲食品等の有効成分としての利用が考えられる。 The body odor control agent for internal use comprising limonene, citronellal, citronellol or citral of the present invention is useful for facilitating community life. The body odor suppressor of the present invention is useful because it has both an immediate effect and a long-lasting effect. That is, since it has an excellent body odor suppressing effect by internal use, it can be used as an active ingredient of pharmaceuticals, supplements, foods and drinks, and the like.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009101565A JP5576621B2 (en) | 2008-04-23 | 2009-04-20 | Body odor suppressor for internal use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008112847 | 2008-04-23 | ||
| JP2008112847 | 2008-04-23 | ||
| JP2009101565A JP5576621B2 (en) | 2008-04-23 | 2009-04-20 | Body odor suppressor for internal use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009280573A true JP2009280573A (en) | 2009-12-03 |
| JP5576621B2 JP5576621B2 (en) | 2014-08-20 |
Family
ID=41451419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009101565A Active JP5576621B2 (en) | 2008-04-23 | 2009-04-20 | Body odor suppressor for internal use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5576621B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011237416A (en) * | 2010-04-16 | 2011-11-24 | Taisho Pharmaceutical Co Ltd | Evaluation method for body odor improving substance |
| JP2013512867A (en) * | 2009-12-04 | 2013-04-18 | ロレアル | Perfume method, perfume kit combining topical fragrance with oral fragrance |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63266A (en) * | 1986-06-19 | 1988-01-05 | Takasago Corp | Method for improving animal smell |
| JP2003089652A (en) * | 2001-09-20 | 2003-03-28 | Meiji Seika Kaisha Ltd | Anti oral cavity candidiasis composition |
| JP2005013138A (en) * | 2003-06-27 | 2005-01-20 | Kiyomitsu Kawasaki | Method for producing spice flavor |
| WO2006129876A1 (en) * | 2005-05-31 | 2006-12-07 | Kanebo Foods, Ltd. | Body odor improving agent for ingestion into body, beverage/food using the same, and method for improvement body odor |
-
2009
- 2009-04-20 JP JP2009101565A patent/JP5576621B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63266A (en) * | 1986-06-19 | 1988-01-05 | Takasago Corp | Method for improving animal smell |
| JP2003089652A (en) * | 2001-09-20 | 2003-03-28 | Meiji Seika Kaisha Ltd | Anti oral cavity candidiasis composition |
| JP2005013138A (en) * | 2003-06-27 | 2005-01-20 | Kiyomitsu Kawasaki | Method for producing spice flavor |
| WO2006129876A1 (en) * | 2005-05-31 | 2006-12-07 | Kanebo Foods, Ltd. | Body odor improving agent for ingestion into body, beverage/food using the same, and method for improvement body odor |
Non-Patent Citations (3)
| Title |
|---|
| "ローザリーナ・ＲＯＳＡＬＩＮＡ [online],2005年4月6日収録", INTERNET ARCHIVE WAYBACK MACHINE,2012年8月31日(検索日),HTTP://WWW.YOGURTSON.COM/JAPANESE/TRADE/SHOP/, JPN6012046850, ISSN: 0002618054 * |
| FLAVOUR FRAGR.J.,2002,17,P.136-40, JPN6012046853, ISSN: 0002618056 * |
| YAMAUCHI, Y. ETAL: "Fractionation of lemon-peel oil by semi-preparative supercritical fluid chromatography", J. CHROMATOGR. A, vol. 505, no. 1, JPN6013042657, 1990, pages 237 - 246, XP026476047, ISSN: 0002618055, DOI: 10.1016/S0021-9673(01)93082-1 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013512867A (en) * | 2009-12-04 | 2013-04-18 | ロレアル | Perfume method, perfume kit combining topical fragrance with oral fragrance |
| JP2011237416A (en) * | 2010-04-16 | 2011-11-24 | Taisho Pharmaceutical Co Ltd | Evaluation method for body odor improving substance |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5576621B2 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0610180A2 (en) | methods for preventing, treating, and treating or controlling a condition associated with inflammation | |
| US20170340569A1 (en) | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases | |
| JPH01294631A (en) | Remedy and preventive for diabetic disease, food and drink and table luxury | |
| JP5467795B2 (en) | β-secretase inhibitor | |
| TW200831134A (en) | Phenylalkyl carbamate compositions | |
| JP2013071909A (en) | Intracerebral lipid peroxide accumulation inhibitor | |
| JP6444583B2 (en) | Oral composition | |
| JP5576621B2 (en) | Body odor suppressor for internal use | |
| WO2005011718A1 (en) | Antistress agent | |
| JP5992305B2 (en) | Composition for improving oral odor | |
| JP2013060427A (en) | Composition for pollakiuria treatment containing loxoprofen and pepper mint extraction | |
| JP3479986B2 (en) | Composition for preventing alcoholic liver injury | |
| TWI275389B (en) | blood | |
| JPH01275522A (en) | Deodorant agent of body smell and uraroma, food and drink and table luxury of deororant for body smell and uraroma | |
| JPH0215032A (en) | Remedy and preventive for liver disease and drink and favorite food having strong liver functionality | |
| JP2014208600A (en) | Composition comprising useful component in turmeric | |
| JP2014207877A (en) | Beverage stably containing useful ingredient in turmeric | |
| JP2007246402A (en) | Liquid formulation for internal use | |
| JP5992304B2 (en) | Oral body odor improving composition | |
| JP5980292B2 (en) | β-secretase inhibitor and acetylcholinesterase inhibitor | |
| TWI292315B (en) | Composition for decreasing lipids in blood | |
| JP4411117B2 (en) | Sleep improvement pharmaceutical composition | |
| EP0326963B1 (en) | Deodorant as well as deodorizing food, drink and seasoning | |
| JP5992308B2 (en) | Oral body odor improving composition | |
| JP5992306B2 (en) | Oral body odor improving composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120409 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130827 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131024 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140623 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140704 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5576621 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |